Wednesday, November 19, 2008
anticoagulans warfarin
Anticogulant medications are high-risk, complex agents, used in settings where the continuum of care is often fragmented. The implementation expectations of NPSG 3E will set a new safe practice standard for anticoagulation therapy in our hospitals nationwide.
The eighth edition of the ACCP Antithrombotic and Thrombolytic Evidenced-Based Clinical Practice Guidelines provides an up-to-date guide for clinical decision making in the treatment of thromboembolic disease. Finally, the promising phase III clinical trials for 2 new drugs, dabigatran and rivaroxapan, may simplify the treatment of thromboembolism. These new drugs are surely a welcome development for patients who have had no alternative to warfarin in more than 60 years.
Medscape gasteroenterology 14 11 2008
